ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that it will have new data featured during late-breaking clinical trial presentations at the upcoming 2016 Transcatheter Cardiovascular Therapeutics educational meeting in Washington, D.C., October 29 – November 2. Throughout the congress, the company will also feature its latest cardiovascular innovations, including PressureWire™ X guidewire, the latest generation of the pioneering PressureWire guidewire system; structural heart solutions and the CardioMEMS™ HF System.
Three late-breaking or first report investigation sessions and one oral abstract presentation will highlight data from St. Jude Medical advancements in vascular and structural heart technologies.
- A comparison of stent visualization technologies for use during percutaneous coronary intervention (PCI) – Data from the first randomized clinical trial to compare OCT-guided, IVUS-guided and angiography-guided PCI
The session: “ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs. IVUS-Guided vs. Angio-Guided Stent Implantation in Patients with Coronary Artery Disease,” will be presented by Dr. Ziad A. Ali, associate director of translational medicine at the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York at 9 a.m. on Sunday, October 30. This is the first late-breaking clinical trial presentation of TCT 2016.
- Final long term results from the RESPECT trial, comparing recurrent stroke in patients with the AMPLATZER™ PFO closure device to contemporary medical management
The session: “RESPECT: Final Long-Term Outcomes from a Prospective, Randomized Trial of PFO Closure in Patients with Cryptogenic Stroke,” will be presented by Dr. David Thaler, neurologist-in-chief at Tufts Medical Center and chairman of the Department of Neurology at Tufts University School of Medicine in Boston, at 12:15 p.m. on Tuesday, November 1.
Previous results observed a stroke reduction across the totality of analyses with rates ranging from 51-73 percent.
- Initial data from the largest, prospective evaluation of the AMPLATZER™ Amulet™ LAA occluder device, designed to seal the left atrial appendage to prevent stroke in patients with non-valvular atrial fibrillation
The session: “AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation,” will be presented by Dr. David Hildick-Smith, cardiologist at Brighton & Sussex University Hospitals in the UK, at 9:40 a.m. on Wednesday, November 2.
Leading interventional cardiologists will also be on hand to demonstrate the OPTIS™ integrated system from 10-11 a.m. and from 2-3 p.m. each day during exhibit hours (Sunday, Oct. 30, Monday, October 31 and Tuesday, November 1).
Additionally, on Sunday, October 31, St. Jude Medical is sponsoring a TCT satellite symposium, "Interventional management of complex patients, cutting edge technologies for the advanced interventionalist.” For more information about this event, visit: http://www.crf.org/tct/agenda/satellite-programs.
About St. Jude Medical
St. Jude Medical is a leading global medical device manufacturer and is dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has five major areas of focus that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management, and cardiovascular. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the company, including potential clinical successes, reimbursement strategies, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the company’s control and the risk factors and other cautionary statements described in the company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 2, 2016. The company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.